LAUSR

Abstract Purpose This study aims to introduce modified fixed field volumetric modulated arc therapy (MF‐VMAT) which manually opened the field size by fixing the jaws and comparing it to the typical planning technique, auto field volumetric modulated arc therapy (AF‐VMAT) in cervical cancer treatment planning. Methods and materials Previously treated twenty‐eight cervical cancer plans were retrospectively randomly selected and replanned in this study using two different planning techniques: AF‐VMAT and MF‐VMAT, resulting in a total of fifty‐six treatment plans. In this study, we compared both planning techniques in three parts: (1) Organ at Risk (OARs) and whole‐body dose, (2) Treatment plan efficiency, and (3) Treatment plan accuracy. Results For OARs dose, bowel bag (p‐value = 0.001), rectum (p‐value = 0.002), and left femoral head (p‐value = 0.001) and whole‐body (p‐value = 0.000) received a statistically significant dose reduction when using the MF‐VMAT plan. Regarding plan efficiency, MF‐VMAT exhibited a statistically significant increase in both number of monitor units (MUs) and control points (p‐values = 0.000), while beam‐on time, maximum leaf travel, average maximum leaf travel, and maximum leaf travel per gantry rotation were statistically significant decreased (p‐values = 0.000). In terms of plan accuracy, the average gamma passing rate was higher in the MF‐VMAT plan for both absolute dose (AD) (p‐value = 0.001, 0.004) and relative dose (RD) (p‐value = 0.000, 0.000) for 3%/3 and 3%/2 mm gamma criteria, respectively. Conclusion The MF‐VMAT planning technique significantly reduces OAR doses and decreases the spread of low doses to normal tissues in cervical cancer patients. Additionally, this planning approach demonstrates efficient plans with lower beam‐on time and reduced maximum leaf travel. Furthermore, it indicates higher plan accuracy through an increase in the average gamma passing rate compared to the AF‐VMAT plan. Consequently, MF‐VMAT offers an effective treatment planning technique for cervical cancer patients.